Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of phase 2 antiviral studies

Phrutsamon Wongnak¹, William HK Schilling^{1,2}, Podjanee Jittamala^{1,3}, Simon

Boyd^{1,2}, Viravarn Luvira⁴, Tanaya Siripoon⁴, Thundon Ngamprasertchai⁴,

Elizabeth M Batty^{1,2}, Shivani Singh^{1,2}, Jindarat Kouhathong¹, Watcharee

Pagornrat¹, Patpannee Khanthagan¹, Borimas Hanboonkunupakarn^{1,4}, Kittiyod

Poovorawan^{1,4}, Mayfong Mayxay^{2,5,6}, Kesinee Chotivanich^{1,4}, Mallika Imwong^{1,7},

Sasithon Pukrittayakamee^{1,4}, Elizabeth A Ashley^{2,5}, Arjen M Dondorp^{1,2}, Nicholas

PJ Day^{1,2}, Mauro M Teixeira⁸, Watcharapong Piyaphanee⁴, Weerapong Phumratanaprapin⁴, Nicholas J White^{1,2,†}, James A Watson^{2,9,†}, on behalf of the **PLATCOV** Collaborative Group

^{*}For correspondence: jwatowatson@gmail.com; nickw@tropmedres.ac

[†]Equal contribution

¹ Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10400, Thailand;

² Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, New Richards Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7LG, UK;

³ Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand:

⁴ Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand;

⁵ Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao P.D.R.;

⁶ Institute for Research and Education Development, University of Health Sciences, Vientiane, Lao P.D.R.;

⁷ Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.:

⁸ Clinical Research Unit, Center for Advanced and Innovative Therapies, Universidade Federal de Minas Gerais, Brazil;

⁹ Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background Effective antiviral drugs prevent hospitalisation and death in COVID-19. Antiviral efficacy can be assessed efficiently in-vivo by measuring rates of SARS-CoV-2 clearance estimated from serial viral densities measured in nasopharyngeal or oropharyngeal swab eluates. The changing epidemiology of SARS-CoV-2 infection has substantially affected viral clearance kinetics and thus the optimal design and interpretation of antiviral pharmacometric evaluations.

Methods Serial viral density data were analysed from patients enrolled in a large multicentre randomised adaptive pharmacodynamic platform trial (PLATCOV) comparing antiviral interventions for SARS-CoV-2. Viral clearance rates over one week were estimated and bootstrap re-sampling was used to assess the optimal duration of follow-up for pharmacometric assessment, where optimal is defined as maximising the expected z-score.

Results Between 29 September 2021 and 20 October 2023, 1264 patients were randomised. Unblinded data were available from 800 patients (16,818 oropharyngeal viral qPCR measurements). SARS-CoV-2 viral clearance was biphasic (bi-exponential). The first phase (α) was accelerated by effective interventions. For all the effective interventions studied, maximum discriminative power (maximum expected z-score) was obtained when evaluating serial data from the first 5 days after enrolment. Over the two year period studied, median viral clearance half-lives estimated over 7 days have shortened from 16.8 hours in September 2021 to 9.3 hours in October 2023 in patients receiving no antiviral drugs, equivalent to a relative reduction of 44% [95% credible interval (CrI): 17 to 67%]. A parallel trend was observed in treated patients. In the ritonavir-boosted nirmatrelvir arm the median clearance half-life declined from 6.6 hours in June 2022 to 4.8 hours in October 2023, a relative reduction of 26% [95%CrI: -4 to 42%].

Conclusions SARS-CoV-2 viral clearance kinetics in symptomatic vaccinated individuals have accelerated substantially over the past two years. Antiviral efficacy in COVID-19 can now be assessed efficiently in-vivo using serial qPCRs from duplicate oropharyngeal swab eluates taken daily for 5 days after drug administration.

Funding Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.

perpetuity. It is made available under a CC-BY 4.0 International license .

¹ Background

Effective SARS-CoV-2 antivirals taken early in the course of COVID-19 illness accelerate viral 2 clearance, hasten symptom resolution, reduce transmission, and lower the probability of progression 3 to severe disease [1-4]. Several small molecule drugs and monoclonal antibodies have proven an-4 tiviral efficacy in COVID-19, although monoclonal antibodies are no longer used widely as immune 5 evasion resulting from viral evolution has reduced or abrogated their antiviral effects. Currently 6 the most effective approved small molecule antiviral drug is ritonavir-boosted nirmatrelvir, a main 7 (3C-like) protease inhibitor [5]. Nirmatrelvir reduces progression to severe disease in an unvacci-8 nated high-risk population by around 90% [3]. But the combination drug is expensive, ritonavir 9 is contraindicated in many individuals because of drug-drug interactions, and ritonavir-boosted 10 nirmatrely regulation in dyspectation [3]. The development of better tolerated drugs (for 11 example ensitrelyir, also a main protease inhibitor [6]) which could be administered more widely 12 would be of considerable public health value, particularly if they were affordable. To guide policies 13 and practices the antiviral activities of new drugs need to be evaluated in comparison with current 14 treatments. 15

The natural history of SARS-CoV-2 infection has changed markedly over the past four years 16 since the beginning of the pandemic. Serious clinical outcomes, notably life-threatening inflam-17 matory pneumonitis, are now very rare. As a result it has become very difficult to demonstrate 18 clinical efficacy for new antiviral drugs because the required sample sizes have become prohibitively 19 large. This was illustrated in the very large PANORAMIC trial of molnupiravir in the UK where 20 only 203 primary events were observed in >25,000 randomised at risk patients [7]. An alternative 21 approach is to use rates of in-vivo viral clearance to characterise and compare antiviral efficacies 22 [8]. This is relatively straightforward and requires orders of magnitude fewer patients [9]. We have 23 demonstrated previously the utility of this approach in identifying ineffective drugs, and assessing 24 and comparing those which are clinically effective [5, 9-11]. 25

The PLATCOV trial is an ongoing multicentre phase 2 adaptive, open label, randomised, 26 pharmacometric platform trial in symptomatic low risk adults with COVID-19 (NCT05041907) 27 [9]. PLATCOV screens candidate antiviral drugs efficiently and compares their in-vivo antiviral 28 effects. Since September 2021 over 1,300 patients have been randomised across six sites in four 29 countries, reporting results for ivermectin [9], remdesivir [12], the monoclonal antibody cocktail 30 casirivimab/imdevimab [10], favipiravir [11], and molnupiravir versus ritonavir boosted nirma-31 trelvir [5]. In this paper we present an analysis of viral clearance in all patients with unblinded 32 data in the PLATCOV study in order to characterise temporal changes in viral kinetics and re-33 assess the optimal approach for characterising and comparing antiviral effects in-vivo. 34

35 Methods

³⁶ The PLATCOV trial

PLATCOV is an ongoing, open-label, multicentre, phase 2, randomised, controlled, adaptive phar-37 macometric platform trial in Thailand, Brazil, Pakistan, and Laos. The trial provides a standard-38 ised quantitative comparative method for in-vivo assessment of potential antiviral treatments in 39 adults at low risk with early symptomatic COVID-19. The primary endpoint is the rate of viral 40 clearance estimated under a linear model fitted to the log viral load (measured by qPCR in daily 41 duplicate oropharyngeal viral swab eluates) data currently sampled on Day 0 and over 7 days of 42 follow-up (8 days in total), denoted α_{0-7} . All patients receive standard symptomatic treatment. 43 PLATCOV is coordinated and monitored by the Mahidol Oxford Tropical Medicine Research 44 Unit (MORU) in Bangkok. The trial was overseen by a trial steering committee and was conducted 45 according to Good Clinical Practice principles. PLATCOV is registered at ClinicalTrials.gov, 46 NCT05041907. 47

48 Ethics statement

⁴⁹ The trial was approved by the Oxford University Tropical Research Ethics Committee (Oxford,

50 UK) and ethics committees in each country. The results were reviewed regularly by a data and

⁵¹ safety monitoring board. In Thailand the trial was approved by the Faculty of Tropical Medicine

52 Ethics Committee, Mahidol University, (reference TMEC 21-058); in Brazil by the Research Ethics

perpetuity. It is made available under a CC-BY 4.0 International license .

Committee of the Universidade Federal de Minas Gerais (COEP-UFMG, Minas Gerais, Brazil, 53 COEP-UFMG) and National Research Ethics Commission- (CONEP, Brazil, COEP-UFMG and 54 CONEP Ref: CAAE:51593421.1.0000.5149); in Laos by the National Ethics Committee for Health 55 Research (NECHR, Lao People's Democratic Republic, Submission ID 2022.48) and the Food & 56 Drugs Department (FDD, Lao People's Democratic Republic, 13066/FDD 12Dec2022); in Pak-57 istan by the National Bioethics Committee (NBC No.4-87/COVID-111/22/842) the Ethics Re-58 view Committee (ERC 2022-7496-21924) and the Drug Regulatory Authority (DRAP Ref: No.03-59 18/2022-CT (PS)). 60

61 Participants

Eligible participants were previously healthy adults aged 18–50 years who gave fully informed con-62 sent for full participation in the study. The entry criteria were: (i) SARS-CoV-2 positive as defined 63 either as a nasal lateral flow antigen test that became positive within 2 minutes (STANDARD Q 64 COVID-19 Ag Test, SD Biosensor, Suwon-si, South Korea) or a positive PCR test with a cycle 65 threshold value less than 25 (all viral gene targets) within the previous 24 h (both these tests ensure 66 the majority of recruited patients have high viral densities; (ii) reported symptoms of COVID-19 67 for less than 4 days (<96 h); (iii) oxygen saturation on room air >96% measured by pulse oximetry 68 at the time of screening; (iv) unimpeded in activities of daily living; (v) agreed to adhere to all 69 procedures, including availability and contact information for follow-up visits. 70

Exclusion criteria included taking any concomitant medications or drugs, chronic illness or 71 condition requiring long-term treatment or other clinically significant comorbidity, laboratory ab-72 normalities at screening (haemoglobin < 8 g/dL, platelet count $< 50.000/\mu$ L, abnormal liver function 73 tests, and estimated glomerular filtration rate $<70 \text{ mL/min per } 1.73 \text{ m}^2$), pregnancy (a urinary 74 pregnancy test was performed in females), actively trying to become pregnant, lactation, con-75 traindication or known hypersensitivity to any of the proposed therapeutics, currently participating 76 in a COVID-19 therapeutic or vaccine trial, or evidence of pneumonia (although imaging was not 77 required). After a detailed explanation of study procedures and requirements all patients provided 78 fully informed written consent. 79

Block randomisation was performed for each site via a centralised web-based application. At 80 enrolment, after obtaining fully informed consent and entering the patient details, the app provided 81 the study drug allocation. The no study drug group comprised a minimum proportion of 20%82 of patients at all times, with uniform randomisation ratios applied across the active treatment 83 groups. The laboratory team were masked to treatment allocation and the clinical investigators 84 were masked to the virology results until the study group was terminated. Apart from the trial 85 statisticians (JAW and PW), the clinical investigators were all masked to the quantitative PCR 86 (qPCR) results. 87

88 Procedures

All treatments were directly observed. Oropharyngeal swabs were taken as follows. A flocked swab 89 (Thermo Fisher MicroTest [Thermo Fisher, Waltham, MA, USA] and later COPAN FLOQSwabs 90 [COPAN Diagnostics, Murrieta, CA, USA]) was rotated against the tonsil through 360° four times 91 and placed in Thermo Fisher M4RT (Thermo Fisher, Waltham, MA, USA) viral transport medium 92 (3 mL). Swabs were transferred at 4–8°C, aliquoted, and then frozen at -80°C within 48 h. 93 On day 0, after randomisation four separate swabs (two swabs from each tonsil) were taken. 94 Separate swabs from each tonsil were then taken once daily from day 1 to day 7, on day 10, and on 95 day 14. Each swab was processed and tested separately. Vital signs were recorded three times daily 96

⁹⁷ by the patient (initial vital signs on the first day were recorded by the study team), and symptoms ⁹⁸ and any adverse effects were recorded daily. The TaqCheck SARS-CoV-2 Fast PCR Assay (Applied ⁹⁹ Biosystems, Thermo Fisher Scientific, Waltham, MA, USA) quantitated viral density (RNA copies ¹⁰⁰ per mL). This multiplexed real-time PCR method detects the SARS-CoV-2 N and S genes, and ¹⁰¹ human RNase P gene in a single reaction. Whole-genome sequencing was performed to identify

¹⁰² viral variants and allocate genotypes.

¹⁰³ Drugs evaluated

¹⁰⁴ The drugs or monoclonal antibodies evaluated were ivermectin (until 11th April 2022); remdesivir

¹⁰⁵ (until 10th June 2022); casirivimab/imdevimab (Thailand only, until 20th October 2022); favipiravir

perpetuity. It is made available under a CC-BY 4.0 International license .

(until 30th October 2022); molnupiravir (until 22nd February 2023); fluoxetine (until 8th May
2023, data not included in this analysis); tixagevimab/cilgavimab (until 4th July 2023. data not
included in this manuscript); nitazoxanide (Brazil, Laos and Pakistan, from 18th January 2022,
ongoing); ensitrelvir (Thailand and Laos only, from 17th March 2023, ongoing); and ritonavirboosted nirmatrelvir (from 6th June 2022, ongoing as positive control). All treatment doses were
either directly observed or video observed.

¹¹² Statistical analysis

113 Data pre-processing

Oropharyngeal eluate viral densities were quantified by PCR on 96-well plates. Each plate con-114 tained 10 or 12 ATCC controls (Manassas, VA, USA; these are heat-inactivated SARS-CoV-2 115 viruses [VR-1986HK strain 2019-nCoV/USAWA1/2020]) varying from 10 to 10⁶ copies per mL. 116 This was a multiplex PCR which also quantifies human RNase P. We first fitted a mixed-effects 117 linear model to all control data from all available plates (using R package lme4 [13]) with the 118 copies per mL on the \log_{10} scale. Visual checks were done to make sure that controls on all plates 119 were in a reasonable range. The mixed-effects model was then used to transform the observed CT 120 values for the oropharyngeal eluate into \log_{10} genomes per mL. A CT value of 40 was considered 121 left-censored and the plate specific censoring value was used in subsequent analyses. 122

123 Baseline viral densities

The baseline viral density was defined as the geometric mean of the oropharyngeal eluate SARS-CoV-2 densities from the four independent swabs taken before randomisation. The temporal trend of baseline viral density was explored using generalised additive models (GAM) with penalised splines, as implemented in the *mgcv* package [14]. As the timing of patient recruitment relative to their onset of symptoms could have also changed over time (and this could affect baseline viral densities), the temporal effect was stratified by the reported number of days since symptom onset.

¹³⁰ Bayesian hierarchical model to estimate average viral clearance rates

The analysis of the serial viral density data used the same analytical model as published previously 131 [5, 9-12]. Patients were included in this analysis if they had been randomised to a currently 132 unblinded treatment arm and had at least 2 days of follow-up (in order to estimate a clearance 133 slope). The main analytical model is a hierarchical Bayesian linear model whereby the log viral 134 densities are modelled as a linear function of time since randomisation, with a random intercept and 135 a random slope for each patient. This hierarchical linear model uses the human RNase P CT value 136 (standardised to have mean zero and standard deviation 1) as an independent additive covariate 137 for each observed \log_{10} viral density. Additional covariate terms on the slope and intercept are 138 the reported days since symptom onset, study site, age, and number of vaccines received. The 139 treatment effect relative to a reference intervention (e.g. no study drug) is parameterised in two 140 ways: (i) a proportional change; and (ii) an additive change in the mean viral clearance rate (the 141 slope of the viral density decay on the log scale is the rate of clearance). Model comparison between 142 the two parameterisation approaches was done using leave-one-out in the package loo [15]. 143

All viral densities below the lower limit of quantification (defined as a CT value of 40) were treated as left-censored (the likelihood is the integral of the likelihood function below the censoring value). The linear model fitted to data between days 0 and $T_{\rm max}$ then estimates the average clearance rate of the period up to $T_{\rm max}$. The rate of viral clearance up until $T_{\rm max}$ is denoted $\alpha_0 - T_{\rm max}$.

¹⁴⁹ Temporal changes in viral clearance dynamics

¹⁵⁰ To assess the temporal changes in viral clearance we added a penalised B-spline of degree 4 to the

¹⁵¹ baseline viral clearance in the reference arm (for most analyses this is the no study drug arm).

¹⁵² This is done by having many knots at regular intervals (chosen to be 10 in the main analysis), but

¹⁵³ with an informative penalisation prior on parameter changes across knots. The penalisation prior

¹⁵⁴ governs the smoothness of the spline fit (https://github.com/milkha/Splines_in_Stan).

perpetuity. It is made available under a CC-BY 4.0 International license .

155 Evaluation of the optimal design

We assessed the optimal follow-up duration by estimating the expected z-score as a function of 156 the number of days of follow-up included in the linear model for six separate intervention com-157 parisons (only using concurrently randomised patients): remdesivir versus no study drug; casiriv-158 imab/imdevimab versus no study drug; molnupiravir versus no study drug; ritonavir-boosted nir-159 matrelvir versus no study drug; and ritonavir-boosted nirmarelvir versus molnupiravir. The data 160 for ritonavir-boosted nirmatrelvir versus no study drug spanned 16 months with a brief hiatus 161 in recruitment in January 2023. We therefore arbitrarily split these data into two separate com-162 parisons, before February 2023 and after February 2023. This allowed assessment of how much 163 the temporal changes in viral clearance was driving the observed results. For each of these six 164 comparisons, and for each maximum follow-up duration (from day 2 to day 14), we bootstrapped 165 the data 50 times (sampling the patients with replacement) and fitted the linear model to estimate 166 the treatment effect and standard error (defined by the width of the 95% credible interval around 167 the posterior treatment estimate). 168

¹⁶⁹ Analysis code

¹⁷⁰ All Bayesian models are written in stan and fitted using the *rstan* interface [16]. All analyses were ¹⁷¹ done using R programming language version 4.3.2 [17].

¹⁷² Data Sharing Statement

All data and code necessary to reproduce the results in this analysis are openly available at https: //github.com/jwatowatson/Determinants-viral-clearance

175 **Results**

176 Patient cohort

Between the 29th September 2021 and 20th October 2023, 1262 patients were randomised in the 177 PLATCOV trial across six sites in four countries (Thailand, Brazil, Pakistan, and Laos). Patients 178 randomised to ensitelvir, combination treatment of ritonavir-boosted nirmatrelvir and molnupi-179 ravir, and nitazoxanide are not included in this analysis as those comparisons are ongoing and their 180 data are still blinded (Figure 1). Patients randomised to fluoxetine and tixagevimab/cilgavimab 181 are not included as the primary analysis of their data has not been published yet (the analysis of 182 the fluoxetine data are provided in an accompanying manuscript [18]). The analysis population, 183 after excluding patients who withdrew consent or who had fewer than 2 days follow-up, consisted 184 of 800 patients randomised between seven arms (not all concurrently) (Supplementary Figure S1). 185 Nearly all included patients were fully vaccinated before the onset of symptoms (> 95%, Table 186 1). The majority (85%) of patients were randomised at one site in Thailand (Hospital for Tropical 187 Diseases [HTD], Bangkok). The mean time from symptom onset to enrolment (first swabs on 188 Day 0) was 2.1 days and the geometric mean baseline viral density in oropharyngeal eluates was 189 approximately 5.5 \log_{10} genomes per mL. 190

¹⁹¹ Baseline viral densities

The baseline viral densities remained high over the two year period (Supplementary Figure S2). 192 There were systematic trends over time in the baseline viral densities, associated with different 193 SARS-CoV-2 variants. The reported number of days since symptom onset was negatively corre-194 lated with the baseline viral density (correlation coefficient $\rho = -0.22$ [95% confidence interval (CI): 195 -0.29; -0.16; $R^2 = 0.05$) (Figure 2B). Each reported additional day since symptom onset corre-196 sponded to a 2.2-fold decrease in the baseline viral density. There were small changes in the mean 197 reported number of days since symptom onset over time. For example, during the Omicron BA.1 198 wave patients were recruited slightly later on average, Figure 2A. In a multivariable spline model 199 stratified by the number of reported days since symptom onset, there was evidence of systematic 200 temporal changes in baseline viral density over time (i.e. not explained by differences in time 201 from symptom onset, Figure 2C). As these are observational data it is not possible to determine 202 causality (e.g. whether these differences are due to variant specific mutations in the spike protein) 203






Figure 1: PLATCOV trial profile and selection of patients used in this analysis. This analysis includes patients enrolled between 30th September 2021 and 20th October 2023 who met the modified intention to treat (mITT) criteria and whose viral clearance data have been unblinded and published.

	No study drug	Ritonavir- boosted nirmatrelvir	Favipiravir	Casirivimab/ imdevimab	Remdesivir	Molnupiravir	Ivermectin
No. of pa-	263	158	114	88	67	66	44
tients							
Brazil	26	4	16	0	9	0	0
Thailand	230	150	98	88	58	65	44
Laos	3	4	0	0	0	1	0
Pakistan	4	0	0	0	0	0	0
Age (years)	31.1 (8.1)	31.3(8.9)	30.2(7.5)	27.9(7.3)	30.1(8.2)	31.3(7.5)	30.0 (7.0)
Female $(\%)$	65.8	69.0	62.3	62.5	52.2	56.1	54.5
Weight (kg)	63.0(13.6)	61.5(12.3)	63.0(13.6)	60.4(12.3)	63.9(11.0)	63.4(14.7)	61.6(12.3)
BMI	23.2(4.1)	23.0(3.8)	23.1(3.7)	22.1(3.1)	22.7(3.1)	23.1(4.0)	22.3 (3.2)
Symptom onset (days)	2.1 (0.8)	1.9 (0.7)	2.1 (0.7)	2.2(0.8)	2.4(0.8)	2.1 (0.7)	2.3 (0.8)
$\begin{array}{c c} Admission \\ viral & load \\ (log_{10} \\ genomes/mL) \end{array}$	5.6 (4.7-6.4) *	5.6 (4.6-6.4)	5.5 (4.7-6.2)	5.7 (5.0-6.4)	5.3 (4.8-6.3)	5.8 (5.0-6.4)	5.6 (5.0-6.6)
Vaccinated (%)	96.2	96.8	98.2	96.6	95.5	98.5	97.7
Start date Finish date	Sep 29, 2021 Oct 20, 2023 (ongoing)	Jun 5, 2022 Oct 20, 2023 (ongoing)	Oct 10, 2021 Oct 29, 2022	Oct 1, 2021 Oct 19, 2022	Oct 4, 2021 Jun 7, 2022	Jun 5, 2022 Feb 14, 2022	Sep 29, 2021 Apr 11, 2022
Delta	10(3.8)	0 (0.0)	11 (9.6)	13(14.8)	10(14.9)	0 (0.0)	12(27.3)
BA.1	13 (4.9)	0 (0.0)	21(18.4)	15(17.0)	20(29.9)	0 (0.0)	14 (31.8)
BA.2	52(19.8)	1(0.6)	42(36.8)	30(34.1)	37(55.2)	5(7.6)	18 (40.9)
BA.2.75	43(16.3)	30(19.0)	5(4.4)	5(5.7)	0 (0.0)	28(42.4)	0 (0.0)
BA.4	2(0.8)	3(1.9)	3(2.6)	0 (0.0)	0 (0.0)	2(3.0)	0(0.0)
BA.5	42 (16.0)	26(16.5)	32(28.1)	25(28.4)	0 (0.0)	28(42.4)	0 (0.0)
XBB	29 (11.0)	22(13.9)	0 (0.0)	0 (0.0)	0 (0.0)	3(4.5)	0 (0.0)
XBB.1.5- like	67 (25.5)	75 (47.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Other	5(1.9)	1 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Table 1: Baseline demographics in the analysis population.






Figure 2: Changes in symptoms duration at enrollment and baseline viral densities over a two year period (2021-2023). Panel A: relationship between reported time since symptom onset and baseline viral density; panel B: temporal changes in the reported time since symptom onset. The vertical dashed line indicates the first Omicron BA.1 infection enrolled in the study; panel C: temporal changes in the baseline viral density stratified by reported time since symptom onset. Red lines and shaded area represent spline model fits and the 95% confidence intervals, respectively.

but the data are compatible with higher peak viral density in specific variants such as BA.2 and 204 XBB.1.5-like. 205

Viral clearance rates over time 206

Viral clearance in COVID-19 follows an approximate bi-exponential (biphasic) decay pattern [19– 207 21]. Previous studies have shown that effective antiviral interventions increase the rate of viral 208 clearance in the first phase [8, 22]. The effect of antivirals on the second phase is less clear and of 209 lesser importance as viral densities are usually fairly low (i.e. unlikely to be transmissible), close 210 to the limit of detection, and clear spontaneously in individuals who are not immunocompromised. 211 The majority of small molecule drugs are given for up to 5 days (e.g. remdesivir, molnupiravir, 212 ritonavir-boosted nirmatrelvir) and have short elimination half-lives. Thus, the primary aim of the 213 PLATCOV trial was to characterise and compare antiviral effects during the first phase of viral 214 clearance. For this reason the primary endpoint included measured viral densities only up until 215 day 7 (day 10 and 14 viral densities were used for the secondary endpoints). We explore here how 216 viral clearance rates have changed over the course of the study and how this impacts the optimal 217 design of pharmacometric assessments. 218

The viral clearance dynamic has become substantially faster over the two years of the trial, 219 as clearly observed in patients in the no study drug arm (see Supplementary Figure S3). The 220 serial viral load data were analysed under a hierarchical Bayesian linear model whereby temporal 221 changes in the average viral clearance rate between days 0 to 7 in the no study drug arm (α_{0-7}) 222




Figure 3: Individual patient rates of viral clearance between days 0 and 7 (α_{0-7}). Average clearance rates for each intervention (coloured lines) and the no study drug arm (black line) are estimated from a spline fit (treatment effects parameterised as proportional change in rate). Vertical lines show 95% credible intervals under the linear model. A negative sign of the clearance rate indicates a decreasing directional change in viral density.

were modelled using penalised B-splines. Figure 3 shows the individual clearance rate estimates. 223 Over the course of two years, viral clearance rates increased substantially. In the no study drug 224 arm, median clearance rates have approximately doubled from -0.43 $(\log_{10}\,{\rm units})/{\rm day}$, which cor-225 responds to a half life of around 16.8 hours, in September 2021, to -0.78/day in October 2023, which 226 corresponds to a half-life of around 9.3 hours. This change corresponds to a relative acceleration in 227 viral clearance half-life of 44% [95%CrI: 17 to 67%] over two years. Similar trends are also noted 228 for the treated individuals. For example, the mean viral clearance rate in the ritonavir-boosted 229 nirmatrelvir arm has increased from -1.10/day (equivalent to a half-life of 6.6 hours) in June 2022 230 to -1.49/day (equivalent to a half-life of 4.8 hours) in October 2023 (Figure 3F), which corresponds 231 to a relative acceleration in viral clearance half-life of 26% [95%CrI: -4 to 42%]. Interestingly, the 232 reduction of viral clearance half-life was most apparent earlier in the study during the transition 233 from Delta in September-December 2021 to BA.2 variant in mid-February 2022 (Figure 4). Sub-234 sequently, the half-life plateaued at around 12.5 hours during the BA.2, BA.4, BA.5, and BA.2.75 235 variants, and gradually reduced again after the emergence of XBB and XBB.1.5-like variant after 236 January 2023. 237

²³⁸ Optimising trial design

In light of the substantial changes observed in the viral clearance rates α_{0-7} over the past two 239 years, we used the available comparative data to assess the optimal duration of follow-up for phar-240 macometric assessment and thus the rapid identification and evaluation of effective antivirals. We 241 define 'optimal' as the duration of virologic assessment which maximises the expected z-score (the 242 estimated effect size divided by the standard error) for differences in viral clearance rates when 243 comparing an effective randomised intervention with the concurrent no treatment arm or com-244 paring two concurrently randomised interventions with different antiviral efficacies. An effective 245 intervention is defined as an intervention which accelerates viral clearance relative to a control 246 intervention. We bootstrapped the data (sampling patients in each comparison with replacement) 247 to obtain uncertainty intervals for the z-score estimates for the available comparisons. Figure 5 248 shows the bootstrap z-score estimates for 6 comparisons, as a function of the duration of follow-up 249 data included in the model estimated viral clearance rate (estimated over durations until day 2 up 250





Figure 4: Change over time in the median viral clearance half-life estimated over 7 days in untreated patients. The median population viral clearance half-life (black line) is estimated from a spline fit, with shaded area showing the 95% credible interval. Individual median clearance half-lives are shown for patients in the no study drug, ivermectin or favipiravir arms. Colours show the main viral sub-lineages. The Y-axis was truncated at 30 hours, with ticks on the top axis indicating the timing and viral variant of patients with a clearance half-life above 30 hours.



Days follow-up included

Figure 5: Z-scores for the treatment effect as a function of the follow-up duration. Grey circles represent the estimated z-score for each bootstrap iteration, while red circles (line) show the median estimates across 50 bootstrap iterations per follow-up duration. The vertical dashed line indicates the follow-up duration that maximises z-scores. This ranged between 4 and 5 days of serial sampling. The comparisons only use concurrently randomised controls. Text annotations indicate number of patients in each comparison arm.

until day 14). For all pairwise comparisons there is a clear inverted-parabolic relationship between the z-score and the duration of follow-up. The expected z-score is maximised for durations between 4 and 5 days. This implies that 4-5 days follow-up is optimal when the data are analysed under a linear model framework. Fitting a log linear model over a longer time period systematically reduces the estimate of the slope (i.e. lengthens the half-life) as it incorporates more of the slower β -phase of viral elimination in the estimate.

²⁵⁷ Comparative assessment of antiviral interventions

The interventions studied here (ivermectin, remdesivir, favipiravir, molnupiravir, ritonavir-boosted 258 nirmatrelvir, and casirivimab/imdevimab) were not randomised concurrently (see Supplementary 259 Figure S1). Thus the large observed temporal changes in baseline viral clearance rates will bias 260 cross-comparisons. We attempt to adjust for this temporal confounding by explicitly incorporating 261 into the model the temporal changes in viral clearance rates in the treatment effect estimation. We 262 fit the full Bayesian linear model with a spline term on the baseline clearance rate in the no study 263 drug arm (which spans the entire study period) as a function of the calendar date, with treatment 264 effects parameterised as proportional changes in the average clearance. Modelling the treatment 265 effect as a proportional change on the slope fitted the data better compared to an additive change. 266 Under the model, there is a clear hierarchy between the studied interventions, which remains 267 consistent when estimating treatment effects using the average viral clearance rates up until day 268 5 (α_{0-5}) or up until day 7 (α_{0-7}). Ritonavir-boosted nirmatrelvir has the greatest effect on viral 269 clearance rates (approx 90% increase in average clearance rates α_{0-7} ; approximately 130% increase 270 in average clearance rates α_{0-5}). The small molecule drugs remdesivir and molnupiravir have very 271




Figure 6: Individual patient data meta-analysis of the treatment effect of the six randomised interventions relative to no study drug. Red: treatment effects based on the average clearance rates over 5 days (α_{0-5}); blue: treatment effects based on the average clearance rates over 7 days (α_{0-7}). The models explicitly adjust for temporal changes in viral clearance in the no study drug arm using penalised B-splines. Points: median posterior estimate; thick and thin lines: 80% and 95% credible intervals, respectively.

similar effects (approximately 35% increase in average clearance rates α_{0-7} ; approximately 50 to 60% increase in average clearance rates α_{0-5}). The average treatment effect for the monoclonal antibody casirivimab/imdevimab (this analysis ignores known treatment effect heterogeneity [10]) is also of similar magnitude. This meta-analysis confirms the absence of any measurable effect of high-dose ivermectin or high-dose favipiravir. For all four effective interventions, the analysis using the α_{0-5} average clearance rates estimates substantially larger effect sizes, albeit with slightly wider uncertainty intervals.

279 Discussion

SARS-CoV-2 oropharyngeal clearance rates in uncomplicated COVID-19 infections have become 280 substantially faster over the past two years. Natural viral clearance is now twice as fast as it was in 281 September 2021. In this studied cohort, most of whom were fully vaccinated, waves of different viral 282 variants succeeded each other, following a generally similar pattern to that observed in most areas 283 of the world. There was no strong association between particular viral variants and increases in 284 viral clearance rates. Instead there appears to have been a steady increase in clearance rates across 285 all variants over time. Some variants (e.g. BA.2.75) were clearly associated with higher baseline 286 viral densities, which was not explained by differences in the interval from symptom onset. It is 287 not possible to ascribe with confidence the underlying cause for these higher baseline viral loads, 288 but it would be compatible with either differences in viral replication [23] or differences in tropism 289

perpetuity. It is made available under a CC-BY 4.0 International license .

290 [24].

The substantial acceleration in natural viral clearance over the past two years presumably re-291 flects the interplay between the acquisition of immunity and the antigenic changes in the evolving 292 variants. This acceleration in natural viral clearance has important implications for the assessment 293 of in-vivo antiviral activity. SARS-CoV-2 oro/nasopharyngeal clearance is biphasic [19–21]. Effec-294 tive drugs substantially accelerate the first phase. Two years ago, when viral clearance rates were 295 much slower, the inflexion in the clearance curve (transition from the first to the second slower 296 phase) was close to seven days, so fitting a single rate constant to the log-linear decline in viral 297 densities over seven days incurred relatively little bias. At current rates of viral clearance, the 298 inflexion point is much earlier, so forcing a single rate constant to the serial qPCR values over 299 seven days incurs greater bias resulting in progressive underestimation of the initial phase rate 300 301 of clearance. This is important for historical comparisons of antiviral activity as with any viral clearance measure, drugs today will result in faster viral clearance than they did earlier in the 302 pandemic. Moderately effective drugs evaluated two years ago (e.g. remdesivir) resulted in viral 303 clearance rates that are similar to those in the no treatment arm of the study today. 304

The PLATCOV study has characterised the effect of several antiviral drugs with findings which 305 are generally consistent with earlier clinical trials assessing their efficacy in the prevention of disease 306 progression. Using the observed differences in the viral clearance profiles between effective and 307 ineffective drugs or the no treatment arm allowed determination of the sampling duration which 308 best characterised these differences. The greatest differences between effective and ineffective (or 309 no) drugs were observed for assessments made from serial samples taken over 4-5 days. Although 310 there is substantial inter-individual variation in clearance rates, and also intra-individual variation 311 between the serial viral density estimates, with current viral clearance rates, daily sampling still 312 has adequate discriminatory power. But, if this trend of increasing rapidity of viral clearance 313 continues, then it may be necessary to sample twice daily over a shorter period. Shortening the 314 viral clearance serial sampling to five days simplifies the comparative assessment of antiviral drugs 315 in COVID-19 (although later sampling is still necessary if rebound is being assessed). 316

These data emphasise the critical importance of fixed ratio contemporary comparators in platform trials. Temporal confounding (also known as 'concept drift') across non-currently randomised interventions or for time varying randomisation ratios (this occurs in response adaptive trials) requires model dependent adjustment. Even an ineffective drug will appear effective if compared with a historical control. The exact ranking of all unblinded interventions studied on the platform in the meta-analysis is dependent in part on correct adjustment for the temporal trends. This issue is particularly salient for the comparison between remdesivir and molnupiravir.

SARS-CoV-2 is today predominantly a mild infection in vaccinated individuals which does not 324 require specific antiviral treatment. This justifies the recruitment of patients into the pharmaco-325 metric assessment who receive no specific treatment. But in patients with underlying conditions 326 or the elderly, COVID-19 is still potentially dangerous and specific antiviral treatment is required. 327 There is no reason to believe that antiviral activities are different in these high risk subgroups to 328 those observed in low risk patients enrolled in this study. At the beginning of the pandemic there 329 were no effective interventions and so identifying minor accelerations in viral clearance was rele-330 vant. Today modest acceleration in the rate of viral clearance may still be therapeutically relevant 331 for chemoprevention (see accompanying results on fluoxetine [18]), but it is very unlikely that less 332 effective drugs than those now being used would be deployed for the treatment of symptomatic 333 COVID-19. The simple methodology employed in the PLATCOV trial is efficient, and very well 334 tolerated, and it identifies efficacious antivirals (i.e. with viral clearance rates which are < 20%335 faster than no drug) with sample sizes which are usually less than 40 studied patients per arm. 336

Although this is the largest detailed pharmacometric study in COVID-19 it has some limitations. Most of the patients were studied in Bangkok, Thailand so the temporal trends observed could be different in other parts of the world. The cause of the substantial inter-patient variations in viral clearance and the overall acceleration in viral clearance over the past two years has not been characterised adequately.

In summary, SARS-CoV-2 viral clearance has accelerated substantially over the past two years necessitating a shortening of the sampling time to evaluate and compare antiviral drugs efficiently.

Role of the funding source 344

The funder of the study had no role in study design, data collection, data analysis, data interpre-345 tation, or writing of the report. 346

Acknowledgements 347

NJW is a Principal Research Fellow funded by the Wellcome Trust (093956/Z/10/C). JAW is a Sir 348 Henry Dale Fellow funded by the Wellcome Trust (223253/Z/21/Z). This study is supported by 349 Wellcome Trust grant reference 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator. 350 We thank all the patients with COVID-19 who volunteered to be part of the study. We thank 351 the data safety and monitoring board (Tim Peto, André Siqueira, and Panisadee Avirutnan); the 352 trial steering committee (Nathalie Strub-Wourgaft, Martin Llewelyn, Deborah Waller, and Attavit 353 Asavisanu); Sompob Saralamba and Tanaphum Wichaita for developing the Rshiny randomisation 354 app; and Mavuto Mukaka for invaluable statistical support. We also thank all the staff of the 355 clinical trials unit at MORU, Thermo Fisher for their excellent support with this project, and all 356 the hospital staff at the Hospital for Tropical Diseases, as well as those involved in sample processing 357 in MORU and the processing and analysis at the Faculty of Tropical Medicine, Mahidol University, 358 molecular genetics laboratory, and the malaria laboratory. We thank the Department of Medical 359 Services, Ministry of Public Health, Thailand for the generous support and the donation of the 360 molnupiravir and ritonavir-boosted nirmatrelvir for this study. We thank the MORU Clinical Trials 361 Support Group for data management, monitoring and logistics, and the purchasing, administration 362 and support staff at MORU. 363

This research was partly funded by Wellcome. A CC BY or equivalent licence is applied to 364 the author accepted manuscript arising from this submission, in accordance with the grant's open 365 access conditions. 366

Authorship contributions 367

PW: conceptualisation, data curation, formal analysis, methodology, visualisation and writing-368 original draft; WHKS: conceptualisation, funding acquisition, investigation, methodology, project 369 administration, supervision, validation and writing- original draft; NJW: conceptualisation, fund-370 ing acquisition, methodology, supervision, validation and writing- original draft; JAW: conceptuali-371 sation, data curation, formal analysis, funding acquisition, methodology, visualisation and writing-372 original draft; PJ: investigation, methodology, project administration, supervision, and validation; 373 SB, and SS: investigation, methodology and project administration; VL, TS, TN, BH, and KP: 374 investigation, methodology, and supervision; EMB: data curation, and formal analysis; JK, WPa, 375 and PK: investigation, methodology; MM, and EAA: investigation, supervision, funding acquisi-376 tion; KC and MI: formal analysis, investigation, resources, supervision; SP, AMD, MMT, WPi, 377 WPh: methodology, investigation, resources, supervision; NPJD: funding acquisition, methodol-378 ogy, investigation, resources, supervision; all Authors were involved in writing- review & editing. 379

Conflict of Interest Disclosures 380

The authors have no conflicts of interest. 381

References 382

[1] Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-COV 383 Antibody Combination and Outcomes in Outpatients with Covid-19. New England Journal 384 of Medicine. 2021;385(23):e81. doi:10.1056/NEJMoa2108163. 385


[2] Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early Remdesivir to 386 Prevent Progression to Severe Covid-19 in Outpatients. New England Journal of Medicine. 387


perpetuity. It is made available under a CC-BY 4.0 International license .

- [3] Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral
 Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New England Journal of
 Medicine. 2022;386(15):1397-1408. doi:10.1056/NEJMoa2118542.
- [4] Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes
 V, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. New
 England Journal of Medicine. 2022;386(6):509–520. doi:10.1056/NEJMoa2116044.
- [5] Schilling WHK, Jittamala P, Watson JA, Boyd S, Luvira V, Siripoon T, et al. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. The Lancet Infectious Diseases. 2024;24(1):36–45.
- [6] Yotsuyanagi H, Ohmagari N, Doi Y, Yamato M, Bac NH, Cha BK, et al. Efficacy and Safety
 of 5-Day Oral Ensitrelvir for Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR
 Randomized Clinical Trial. medRxiv (preprint). 2023;doi:10.1101/2023.07.11.23292264.
- ⁴⁰² [7] Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Mol⁴⁰³ nupiravir plus usual care versus usual care alone as early treatment for adults with COVID⁴⁰⁴ 19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive
 ⁴⁰⁵ randomised controlled trial. The Lancet. 2023;401(10373):281–293. doi:10.1016/S0140⁴⁰⁶ 6736(22)02597-1.
- [8] Watson JA, Kissler SM, Day NPJ, Grad YH, White NJ. Characterizing SARS-CoV-2 viral
 clearance kinetics to improve the design of antiviral pharmacometric studies. Antimicrob
 Agents Chemother. 2022;66(7):e0019222.
- [9] Schilling WH, Jittamala P, Watson JA, Ekkapongpisit M, Siripoon T, Ngamprasertchai
 T, et al. Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV). eLife. 2023;12:e83201.
 doi:10.7554/eLife.83201.
- [10] Jittamala P, Schilling WHK, Watson JA, Luvira V, Siripoon T, Ngamprasertchai T, et al.
 Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2
 Delta and Omicron variants. medRxiv. 2022; p. 2022–10.
- [11] Luvira V, Schilling WH, Jittamala P, Watson JA, Boyd S, Siripoon T, et al. Clinical antiviral
 efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled
 adaptive platform trial. BMC Infectious Diseases, in press. 2023;.
- [12] Jittamala P, Schilling WHK, Watson JA, Luvira V, Siripoon T, Ngamprasertchai T, et al.
 Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV). The Journal of Infectious Diseases.
 2023; p. jiad275. doi:10.1093/infdis/jiad275.
- [13] Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4.
 Journal of Statistical Software. 2015;67(1):1 48.
- [14] Wood SN. Fast stable restricted maximum likelihood and marginal likelihood estimation of
 semiparametric generalized linear models. Journal of the Royal Statistical Society, Series B
 (Statistical Methodology). 2011;73(1):3–36. doi:10.1111/j.1467-9868.2010.00749.x.
- [15] Vehtari A, Gelman A, Gabry J. Practical Bayesian model evaluation using leave-one-out cross validation and WAIC. Statistics and Computing. 2017;27(5):1413–1432. doi:10.1007/s11222 016-9696-4.
- [16] Stan Development Team. RStan: the R interface to Stan; 2023. Available from: https:
 //mc-stan.org/.
- [17] R Core Team. R: A Language and Environment for Statistical Computing; 2023. Available
 from: https://www.R-project.org/.
- [18] Jittamala P, Boyd S, Schilling WH, Watson JA, Siripoon T, Luvira V, et al. Antiviral efficacy
 of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive
 platform trial (PLATCOV). Medrxiv. 2024;.


perpetuity. It is made available under a CC-BY 4.0 International license .


- [19] Néant N, Lingas G, Le Hingrat Q, Ghosn J, Engelmann I, Lepiller Q, et al. Modeling SARS CoV-2 viral kinetics and association with mortality in hospitalized patients from the French
 COVID cohort. Proceedings of the National Academy of Sciences. 2021;118(8):e2017962118.
 doi:10.1073/pnas.2017962118.
- [20] Ke R, Martinez PP, Smith RL, Gibson LL, Mirza A, Conte M, et al. Daily longitudinal
 sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. Nature
 Microbiology. 2022;7(5):640-652. doi:10.1038/s41564-022-01105-z.
- [21] Ribeiro RM, Choudhary MC, Deo R, Giganti MJ, Moser C, Ritz J, et al. VariantSpecific Viral Kinetics in Acute COVID-19. The Journal of Infectious Diseases.
 2023;228(Supplement 2):S136–S143. doi:10.1093/infdis/jiad314.
- ⁴⁴⁹ [22] Chew KW, Moser C, Daar ES, Wohl DA, Li JZ, Coombs RW, et al. Antiviral and clinical
 ⁴⁵⁰ activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.
 ⁴⁵¹ Nature Communications. 2022;13(1):4931. doi:10.1038/s41467-022-32551-2.
- [23] Marc A, Marlin R, Donati F, Prague M, Kerioui M, Hérate C, et al. Impact of variants
 of concern on SARS-CoV-2 viral dynamics in non-human primates. PLOS Computational
 Biology. 2023;19(8):1–16. doi:10.1371/journal.pcbi.1010721.
- ⁴⁵⁵ [24] Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, et al. Altered
 ⁴⁵⁶ TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature.
 ⁴⁵⁷ 2022;603(7902):706-714. doi:10.1038/s41586-022-04474-x.






C Temporal dynamics of baseline viral densities by time since symptom onset







Randomisation date





A Remdesivir vs No study drug













C Casirivimab/imdevimab vs No study drug



F Nirmatrelvir vs No study drug (after Feb 2023)



Days follow-up included

Z-score

D

